This is a demo store. No orders will be fulfilled.
USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
04 May 2016 | North America | Market Research
The Transformation of the American Hospital, Assessment to 2020
Focus Shifts from Patient Volumes to Value-based Outcomes and Collaborative Care
The US hospital industry is in the midst of a major transformation of clinical and operational strategy, moving from a “heads to beds” provider-centric delivery system to a collaborative care continuum, with the patient at the epicenter of attention. Research analysis covers how reimbursement cuts and regulatory changes contribute towards the e...
$4,950.00 -
03 May 2016 | North America | Market Research
US Telehealth Virtual Visits Market, Forecast to 2020
Services for the 21st Century House Call
This Frost & Sullivan research service presents a comprehensive analysis of the market potential and dynamics of telehealth virtual visits in the United States. It describes emerging technologies in the telehealth services market and analyses the factors driving the need to deploy virtual or video telehealth solutions across a variety of settings. ...
$4,950.00 -
08 Apr 2016 | North America | Market Research
Global Intensive Care Unit Infrastructure—Comparative Analysis, 2015
Trends Highlight Urgent Need for Cost-effective Critical Care Strategies, Tilt toward Higher ICU Bed Utilization Rates and Reduced Length of Stay (LOS)
Intensive care units (ICUs) are primarily for managing patients with acute or lifethreatening disease or conditions. The critical care provided in the ICUs depends upon the resource availability such as skilled personnel and reliable advanced therapeutic and monitoring equipments. Hence, ICUs contribute to a significant amount of spending despite b...
$3,000.00 -
18 Mar 2016 | North America | Market Research
Vital Signs - Stem Cell Therapy in Ischemic Stroke Recovery
Additional Clinical Trials Critical to Building on Early Promise
As indicated by the World Health Organization, stroke is the second-leading cause of death for people over the age of 60 and is the fifth-leading cause of death for those between the ages of 15 and 59. The incidence of stroke is expected to increase by 25% over the next 20 years. Over 40% of ischemic stroke victims have permanent symptoms and only ...
$450.00 -
18 Mar 2016 | North America | Market Research
Vital Signs - Drug Development Focus on Genetically Modified Swine
Modified Swine Hold out Promise of Improving Pre-Clinical Efficacy, Lowering Multi-billion Dollar Drug and Device Development Costs
The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states ...
$450.00
